SAN DIEGO, Nov. 5, 2015 /PRNewswire/ -- CareFusion, a BD
company (NYSE:BDX), today announced its AirLife business
line has signed an exclusive agreement with ResMed (NYSE:RMD) to
distribute innovative nasal high flow interface products from the
company.
"This agreement with ResMed is aligned with our commitment to
providing high quality respiratory products to our customers," said
Dan Woolson, president of
Respiratory Solutions at BD. "This collaboration will help ensure
our customers have access to a full portfolio of leading
respiratory solutions."
The agreement with ResMed includes exclusive distribution rights
for its AcuCare™ high flow nasal cannula in the
U.S. acute care market. ResMed's nasal cannula offers a fast and
intuitive fit, and is engineered to stay in place once fitted,
providing speed and stability for built-in success in high flow
oxygen therapy.
"The combination of ResMed products with AirLife's reach
will help provide more patients with innovative respiratory
technology," said Jim Hollingshead,
president ResMed Americas. "This collaboration helps position
ResMed for growth beyond what we could achieve alone."
Additional terms of the agreement were not disclosed.
About CareFusion
CareFusion, a BD company, serves the
health care industry with products and services that help hospitals
measurably improve the safety and quality of care. The company
develops industry-leading technologies including Alaris®
infusion pumps and IV sets, MaxPlus® and
MaxZero™ IV connectors and sets, Pyxis®
automated dispensing and patient identification systems,
AVEA®, LTV® series and
AirLife® ventilation and respiratory products,
ChloraPrep® products, MedMined® services for
data mining surveillance, V. Mueller® surgical
instruments, and an extensive line of products that support
interventional medicine. For more information please visit
www.carefusion.com.
About BD
BD is a leading medical technology
company that partners with customers and stakeholders to address
many of the world's most pressing and evolving health needs. Our
innovative solutions are focused on improving medication management
and patient safety; supporting infection prevention practices;
equipping surgical and interventional procedures; improving drug
delivery; aiding anesthesiology and respiratory care; advancing
cellular research and applications; enhancing the diagnosis of
infectious diseases and cancers; and supporting the management of
diabetes. We are more than 45,000 associates in 50 countries who
strive to fulfill our purpose of "Helping all people live
healthy lives" by advancing the quality, accessibility, safety
and affordability of healthcare around the world. In 2015, BD
welcomed CareFusion and its products into the BD family of
solutions. For more information on BD, please visit www.bd.com.
About ResMed
The global team at ResMed (NYSE:RMD) is
united in the commitment to change millions of lives with every
breath. With more than 4,000 employees and a presence in over
100 countries, the company has been pioneering new and innovative
devices and treatments for sleep-disordered breathing, chronic
obstructive pulmonary disease, and other chronic diseases for more
than 25 years. ResMed's world-leading products and innovative
solutions improve the quality of life for millions of patients
worldwide, reduce the impact of chronic disease, and save
healthcare costs. For more information about ResMed and its
businesses, visit http://www.resmed.com or follow @resmed on
Twitter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/carefusion-airlife-signs-new-distribution-agreement-with-resmed-300172965.html
SOURCE CareFusion